Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Total Liabilities (2020 - 2025)

Rani Therapeutics Holdings has reported Total Liabilities over the past 6 years, most recently at $17.1 million for Q4 2025.

  • Quarterly results put Total Liabilities at $17.1 million for Q4 2025, down 48.38% from a year ago — trailing twelve months through Dec 2025 was $17.1 million (down 48.38% YoY), and the annual figure for FY2025 was $17.1 million, down 48.38%.
  • Total Liabilities for Q4 2025 was $17.1 million at Rani Therapeutics Holdings, down from $22.1 million in the prior quarter.
  • Over the last five years, Total Liabilities for RANI hit a ceiling of $118.5 million in Q1 2021 and a floor of $2.6 million in Q4 2021.
  • Median Total Liabilities over the past 5 years was $31.0 million (2023), compared with a mean of $29.2 million.
  • Peak annual rise in Total Liabilities hit 1188.75% in 2022, while the deepest fall reached 96.06% in 2022.
  • Rani Therapeutics Holdings' Total Liabilities stood at $2.6 million in 2021, then soared by 1188.75% to $34.0 million in 2022, then fell by 4.56% to $32.5 million in 2023, then grew by 2.06% to $33.1 million in 2024, then tumbled by 48.38% to $17.1 million in 2025.
  • The last three reported values for Total Liabilities were $17.1 million (Q4 2025), $22.1 million (Q3 2025), and $26.1 million (Q2 2025) per Business Quant data.